Alkermes (ALKS) Shares Pounded after Depression Drug Fails Studies

Shares of Alkermes plc (ALKS) were off -19.92 or -32.97 percent in Thursday's premarket after the company announced the topline results of two phase 3 studies of the company's drug for treatment of depression . Alkermes stock closed at $60.42 per share, up +0.89 or +1.50 percent in Wednesday's regular trading session. Dublin, Ireland based ... READ MORE Read the rest of Alkermes (ALKS) Shares Pounded after Depression Drug Fails Studies at InvestorGuide.com .